SCHEMBL6133354

SCHEMBL6133354

CC(C)n1nc(-c2cnc(N)nc2-c2ccccc2OCCN2CCOCC2)ccc1=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADCY10 Q96PN6 2/20 0.45
KDM4E B2RXH2 1/20 0.43
ADORA2A P29274 2/20 0.43
ADORA1 P30542 2/20 0.43
ADORA3 P0DMS8 1/20 0.43
ADORA2B P29275 1/20 0.43
PDE9A O76083 2/20 0.41
PDE1A P54750 2/20 0.41
PDE1B Q01064 2/20 0.41
PDE1C Q14123 2/20 0.41
PDE5A O76074 1/20 0.41
BRD4 O60885 1/20 0.40
HSP90AA1 P07900 1/20 0.40
HSP90AB1 P08238 1/20 0.40
POLB P06746 2/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
MAPKAPK2 P49137 1/20 0.39
USP2 O75604 1/20 0.39
FGFR1 P11362 1/20 0.39
FGFR2 P21802 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6133313 0.86 ADORA2A (0.50) ADORA2AADORA1ADORA3ADORA2BFGFR1
SCHEMBL6134784 0.85 PDE1A (0.38) KDM4EADORA2AADORA1PDE9APDE1A
SCHEMBL6133482 0.85 ADORA2A (0.51) ADORA2AADORA1ADORA3ADORA2BMAPKAPK2
SCHEMBL6134700 0.84 IDO1 (0.40) ADORA2AADORA1ADORA2BPDE1APDE1B
SCHEMBL6133823 0.84 ADORA1 (0.35) ADORA2AADORA1ADORA2BPDE1APDE1B
SCHEMBL6133847 0.84 LRRK2 (0.39) ADORA2AADORA1PDE1APDE1BPDE1C
SCHEMBL6134186 0.83 ADORA1 (0.34) ADORA2AADORA1ADORA2B
SCHEMBL6133875 0.83 LRRK2 (0.42) ADORA2AADORA1PDE1APDE1BPDE1C
SCHEMBL6135333 0.83 HTR7 (0.39) KDM4EADORA2AADORA1
SCHEMBL6134869 0.83 PDE5A (0.37) ADORA2AADORA1PDE5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050043315-A1 Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them ASTELLAS PHARMA INC. (JP) 2005-02-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050043315-A1 Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them ADORA2B, ADORA2A, ADORA1 ADCY10 811/4885KDM4E 3364/4885ADORA2A 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.